生物标志物预测肝细胞癌患者抗PD-1/PD-L1治疗客观疗效的研究进展  

Research progress of biomarkers in predicting objective efficacy of anti-PD-1/PD-L1 therapy in patients with hepatocellular carcinoma

作　　者：柳利利 张成仁 郝相勇[2] 田宏伟[2] 邓渊 李雄 蒋智良 郭天康[2] LIU Lili;ZHANG Chengren;HAO Xiangyong;TIAN Hongwei;DENG Yuan;LI Xiong;JIANG Zhiliang;GUO Tiankang(Department of First Clinical Medical College of Gansu University of Chinese Medicine,Lanzhou 730030,China;Department of General Surgery,Gansu Provincial People's Hospital,Lanzhou 730030,China;Clinical Medical College of Ningxia Medical University,Yinchuan 750000,China)

机构地区：[1]甘肃中医药大学第一临床医学院,甘肃兰州730030 [2]甘肃省人民医院普通外科,甘肃兰州730030 [3]宁夏医科大学临床医学院,宁夏银川750000

出　　处：《中国普通外科杂志》2022年第7期966-974,共9页China Journal of General Surgery

基　　金：甘肃省自然科学基金资助项目(20JR10RA403)。

摘　　要：近年来,抗PD-1/PD-L1免疫治疗的出现为晚期肝细胞癌(HCC)患者带来了新的希望。然而,临床实践发现大约只有10%~30%的HCC患者才能从抗PD-1/PD-L1的治疗中获益。因此,精确筛选出抗PD-1/PD-L1治疗的获益人群成为目前的一大难题。循证医学证据的不断积累以及精准诊疗生物标志物的迅速发展,为HCC患者抗PD-1/PD-L1的精准治疗提供了有力帮助。生物标志物是免疫治疗的重大突破,不仅可以筛选出免疫治疗的获益人群,还能够避免毒副反应。本文中,笔者主要阐述HCC患者抗PD-1/PD-L1治疗相关生物标志物的研究现状和未来发展。In recent years,anti-PD-1/PD-L1 immunotherapy has brought new hope to patients with advanced hepatocellular carcinoma(HCC).However,only about 10%-30% of the HCC patients can benefit from anti-PD-1/PD-L1 therapy as evidenced by clinical observation.Therefore,the accurate screening of patients suitable for the anti-PD-1/PD-L1 immunotherapy has become a challenge at present.The continuous accumulation of evidence-based knowledge and the rapid development of biomarkers for precision medicine provide powerful help for the precise treatment of anti-PD-1/PD-L1 for HCC patients.The discovery of biomarkers is a major breakthrough in immunotherapy,which can not only screen patients who benefit from immunotherapy,but also avoid toxic and side effects.Here,the authorsmainly address the research status and future development of biomarkers associated with anti-PD-1/PDL1 treatment in HCC patients.

关 键 词：癌 肝细胞 程序性细胞死亡受体1 免疫检查点抑制剂 生物标记 综述 

分 类 号：R735.7[医药卫生—肿瘤]